Callan Family Office LLC Makes New Investment in CVS Health Co. (NYSE:CVS)

Callan Family Office LLC purchased a new position in CVS Health Co. (NYSE:CVS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,165 shares of the pharmacy operator's stock, valued at approximately $905,000.

Several other institutional investors have also modified their holdings of CVS. Hotchkis & Wiley Capital Management LLC grew its stake in shares of CVS Health by 34.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 11,897,034 shares of the pharmacy operator's stock worth $748,085,000 after acquiring an additional 3,071,613 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of CVS Health in the fourth quarter worth $116,033,000. ARGA Investment Management LP grew its stake in shares of CVS Health by 7,567.7% during the fourth quarter. ARGA Investment Management LP now owns 2,402,901 shares of the pharmacy operator's stock worth $107,866,000 after purchasing an additional 2,371,563 shares in the last quarter. State Street Corp grew its stake in shares of CVS Health by 3.6% during the third quarter. State Street Corp now owns 56,527,909 shares of the pharmacy operator's stock worth $3,554,475,000 after purchasing an additional 1,989,066 shares in the last quarter. Finally, TOMS Capital Investment Management LP acquired a new position in shares of CVS Health during the third quarter worth $121,987,000. Institutional investors and hedge funds own 80.66% of the company's stock.

CVS Health Stock Performance

NYSE CVS traded up $1.09 during trading hours on Friday, hitting $66.34. 10,082,148 shares of the stock were exchanged, compared to its average volume of 11,965,158. The company has a market cap of $83.64 billion, a price-to-earnings ratio of 18.12, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. CVS Health Co. has a 12-month low of $43.56 and a 12-month high of $80.75. The stock has a 50-day moving average of $56.42 and a 200 day moving average of $56.75. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

Remove Ads

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. As a group, equities research analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.01%. CVS Health's payout ratio is currently 72.68%.

Analyst Ratings Changes

CVS has been the subject of a number of analyst reports. Truist Financial boosted their target price on shares of CVS Health from $60.00 to $76.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Argus set a $77.00 target price on shares of CVS Health in a research note on Tuesday, February 18th. Royal Bank of Canada lowered their target price on shares of CVS Health from $68.00 to $58.00 and set an "outperform" rating for the company in a research note on Friday, November 15th. StockNews.com raised shares of CVS Health from a "sell" rating to a "hold" rating in a research report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a "hold" rating to a "buy" rating and set a $66.00 price target for the company in a research report on Tuesday, December 3rd. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $69.83.

Insiders Place Their Bets

In other news, SVP James David Clark sold 7,513 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is currently owned by company insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.